Last 12 months
Inside the activity.
1 purchase rows · 2632 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 142 |
| Dec 2025 | 0 | 143 |
| Jan 2026 | 0 | 78 |
| Feb 2026 | 0 | 26 |
| Mar 2026 | 0 | 364 |
| Apr 2026 | 0 | 346 |
| May 2026 | 1 | 340 |
| Jun 2026 | 0 | 298 |
| Jul 2026 | 0 | 240 |
| Aug 2026 | 0 | 251 |
| Sep 2026 | 0 | 260 |
| Oct 2026 | 0 | 144 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 22, 2026 Filed Jul 23, 2026 20:46 UTC |
MAXWELL LINDADirector
|
GrantStock Option · Derivative | 1,190 | $0.00 Strike: $527.07 | $0.00 |
DisclosureSEC source: 0001822674-26-000004 · primarydocument.xml · derivative · entry 2 MAXWELL LINDA · CIK 0001822674 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,190 Underlying: Common Stock · 1,190 shares Expires 2033-07-22 F2 · shares: Annual non-employee director award. F3 · derivative.exercise_date: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:46 UTC |
MAXWELL LINDADirector
|
GrantRestricted Stock Unit · Derivative | 380 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001822674-26-000004 · primarydocument.xml · derivative · entry 1 MAXWELL LINDA · CIK 0001822674 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380 Underlying: Common Stock · 380 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F2 · shares: Annual non-employee director award. F3 · derivative.exercise_date: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:44 UTC |
Tracey KevinDirector
|
GrantRestricted Stock Unit · Derivative | 760 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002107022-26-000005 · primarydocument.xml · derivative · entry 1 Tracey Kevin · CIK 0002107022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 760 Underlying: Common Stock · 760 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F2 · shares: Annual non-employee director award. F3 · derivative.exercise_date: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:45 UTC |
Thompson Tommy GDirector
|
GrantStock Option · Derivative | 1,190 | $0.00 Strike: $527.07 | $0.00 |
DisclosureSEC source: 0001324863-26-000004 · primarydocument.xml · derivative · entry 5 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,190 Underlying: Common Stock · 1,190 shares Expires 2033-07-22 F3 · shares: Annual non-employee director award. F4 · derivative.exercise_date: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:45 UTC |
Thompson Tommy GDirector
|
GrantRestricted Stock Unit · Derivative | 380 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001324863-26-000004 · primarydocument.xml · derivative · entry 4 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380 Underlying: Common Stock · 380 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F3 · shares: Annual non-employee director award. F4 · derivative.exercise_date: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. F5 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:44 UTC |
Olian Judy D.Director
|
GrantRestricted Stock Unit · Derivative | 760 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001605729-26-000013 · primarydocument.xml · derivative · entry 2 Olian Judy D. · CIK 0001605729 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 760 Underlying: Common Stock · 760 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F2 · shares: Annual non-employee director award. F3 · derivative.exercise_date: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:43 UTC |
MALCOLM JANDirector
|
GrantStock Option · Derivative | 1,190 | $0.00 Strike: $527.07 | $0.00 |
DisclosureSEC source: 0002028640-26-000008 · primarydocument.xml · derivative · entry 3 MALCOLM JAN · CIK 0002028640 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,570 Underlying: Common Stock · 1,190 shares Expires 2033-07-22 F2 · shares: Annual non-employee director award. F3 · derivative.exercise_date: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:43 UTC |
MALCOLM JANDirector
|
GrantRestricted Stock Unit · Derivative | 380 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002028640-26-000008 · primarydocument.xml · derivative · entry 2 MALCOLM JAN · CIK 0002028640 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 380 Underlying: Common Stock · 380 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F2 · shares: Annual non-employee director award. F3 · derivative.exercise_date: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:43 UTC |
Mesa NildaDirector
|
GrantStock Option · Derivative | 1,190 | $0.00 Strike: $527.07 | $0.00 |
DisclosureSEC source: 0001756697-26-000003 · primarydocument.xml · derivative · entry 3 Mesa Nilda · CIK 0001756697 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,190 Underlying: Common Stock · 1,190 shares Expires 2033-07-22 F2 · shares: Annual non-employee director award. F3 · derivative.exercise_date: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:43 UTC |
Mesa NildaDirector
|
GrantRestricted Stock Unit · Derivative | 380 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001756697-26-000003 · primarydocument.xml · derivative · entry 2 Mesa Nilda · CIK 0001756697 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380 Underlying: Common Stock · 380 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F2 · shares: Annual non-employee director award. F3 · derivative.exercise_date: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:38 UTC |
CAUSEY CHRISTOPHERDirector
|
GrantStock Option · Derivative | 2,380 | $0.00 Strike: $527.07 | $0.00 |
DisclosureSEC source: 0001237334-26-000006 · primarydocument.xml · derivative · entry 2 CAUSEY CHRISTOPHER · CIK 0001237334 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,380 Underlying: Common Stock · 2,380 shares Expires 2033-07-22 F1 · shares: Annual non-employee director award. F2 · derivative.exercise_date: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:38 UTC |
SULLIVAN LOUIS WDirector
|
GrantStock Option · Derivative | 2,380 | $0.00 Strike: $527.07 | $0.00 |
DisclosureSEC source: 0001193522-26-000002 · primarydocument.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,380 Underlying: Common Stock · 2,380 shares Expires 2033-07-22 F3 · shares: Annual non-employee director award. F4 · derivative.exercise_date: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:37 UTC |
PATUSKY CHRISTOPHERDirector
|
GrantStock Option · Derivative | 2,380 | $0.00 Strike: $527.07 | $0.00 |
DisclosureSEC source: 0001231427-26-000004 · primarydocument.xml · derivative · entry 2 PATUSKY CHRISTOPHER · CIK 0001231427 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,380 Underlying: Common Stock · 2,380 shares Expires 2033-07-22 F1 · shares: Annual non-employee director award. F2 · derivative.exercise_date: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:36 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
Exercise / conversionStock Option · Derivative | 9,500 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001106578-26-000104 · primarydocument.xml · derivative · entry 21 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 293,910 Underlying: Common Stock · 9,500 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F20 · ownership.nature: Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:36 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 80 | $539.47 | $43,157.60 |
DisclosureSEC source: 0001106578-26-000104 · primarydocument.xml · nonDerivative · entry 15 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 324,443 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F16 · price: This transaction was executed in multiple trades at prices ranging from $539.23 to $539.71. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:36 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 680 | $538.46 | $366,153.00 |
DisclosureSEC source: 0001106578-26-000104 · primarydocument.xml · nonDerivative · entry 14 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 324,523 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F15 · price: This transaction was executed in multiple trades at prices ranging from $538.06 to $538.70. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:36 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 570 | $537.60 | $306,433.94 |
DisclosureSEC source: 0001106578-26-000104 · primarydocument.xml · nonDerivative · entry 13 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 325,203 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F14 · price: This transaction was executed in multiple trades at prices ranging from $537.06 to $537.97. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:36 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 790 | $536.49 | $423,826.63 |
DisclosureSEC source: 0001106578-26-000104 · primarydocument.xml · nonDerivative · entry 12 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 325,773 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F13 · price: This transaction was executed in multiple trades at prices ranging from $536.06 to $537.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:36 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 107 | $535.40 | $57,288.07 |
DisclosureSEC source: 0001106578-26-000104 · primarydocument.xml · nonDerivative · entry 11 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 326,563 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F12 · price: This transaction was executed in multiple trades at prices ranging from $534.74 to $535.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:36 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 324 | $534.19 | $173,075.94 |
DisclosureSEC source: 0001106578-26-000104 · primarydocument.xml · nonDerivative · entry 10 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 326,670 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F11 · price: This transaction was executed in multiple trades at prices ranging from $533.65 to $534.635. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:36 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 489 | $533.24 | $260,755.53 |
DisclosureSEC source: 0001106578-26-000104 · primarydocument.xml · nonDerivative · entry 9 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 326,994 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F10 · price: This transaction was executed in multiple trades at prices ranging from $532.61 to $533.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:36 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 400 | $531.22 | $212,489.80 |
DisclosureSEC source: 0001106578-26-000104 · primarydocument.xml · nonDerivative · entry 8 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 327,483 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F9 · price: This transaction was executed in multiple trades at prices ranging from $530.80 to $531.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:36 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 760 | $529.80 | $402,644.50 |
DisclosureSEC source: 0001106578-26-000104 · primarydocument.xml · nonDerivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 327,883 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F8 · price: This transaction was executed in multiple trades at prices ranging from $529.45 to $530.28. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:36 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 874 | $528.91 | $462,264.89 |
DisclosureSEC source: 0001106578-26-000104 · primarydocument.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 328,643 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F7 · price: This transaction was executed in multiple trades at prices ranging from $528.37 to $529.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:36 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 1,211 | $527.82 | $639,188.81 |
DisclosureSEC source: 0001106578-26-000104 · primarydocument.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 329,517 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F6 · price: This transaction was executed in multiple trades at prices ranging from $527.37 to $528.36. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:36 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 2,610 | $526.84 | $1,375,057.88 |
DisclosureSEC source: 0001106578-26-000104 · primarydocument.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 330,728 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F5 · price: This transaction was executed in multiple trades at prices ranging from $526.36 to $527.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:36 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 485 | $526.04 | $255,130.95 |
DisclosureSEC source: 0001106578-26-000104 · primarydocument.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 333,338 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F4 · price: This transaction was executed in multiple trades at prices ranging from $525.35 to $526.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:36 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 120 | $524.27 | $62,912.40 |
DisclosureSEC source: 0001106578-26-000104 · primarydocument.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 333,823 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F3 · price: This transaction was executed in multiple trades at prices ranging from $524.15 to $524.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:36 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
Exercise / conversionCommon Stock | 9,500 | $135.42 | $1,286,490.00 |
DisclosureSEC source: 0001106578-26-000104 · primarydocument.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 333,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:37 UTC |
Giltner RichardDirector
|
GrantRestricted Stock Unit · Derivative | 760 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001460472-26-000002 · primarydocument.xml · derivative · entry 2 Giltner Richard · CIK 0001460472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 760 Underlying: Common Stock · 760 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F2 · shares: Annual non-employee director award. F3 · derivative.exercise_date: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| July 21, 2026 Filed Jul 22, 2026 20:30 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
Exercise / conversionStock Option · Derivative | 9,500 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001106578-26-000103 · primarydocument.xml · derivative · entry 18 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 303,410 Underlying: Common Stock · 9,500 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F16 · ownership.nature: Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries. Read SEC document |
| July 21, 2026 Filed Jul 22, 2026 20:30 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 839 | $536.37 | $450,017.95 |
DisclosureSEC source: 0001106578-26-000103 · primarydocument.xml · nonDerivative · entry 12 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 324,443 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F12 · price: This transaction was executed in multiple trades at prices ranging from $536.36 to $537.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 21, 2026 Filed Jul 22, 2026 20:30 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 341 | $535.44 | $182,585.72 |
DisclosureSEC source: 0001106578-26-000103 · primarydocument.xml · nonDerivative · entry 11 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 325,282 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F11 · price: This transaction was executed in multiple trades at prices ranging from $535.24 to $536.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 21, 2026 Filed Jul 22, 2026 20:30 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 1,760 | $534.61 | $940,922.05 |
DisclosureSEC source: 0001106578-26-000103 · primarydocument.xml · nonDerivative · entry 10 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 325,623 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F10 · price: This transaction was executed in multiple trades at prices ranging from $534.17 to $535.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 21, 2026 Filed Jul 22, 2026 20:30 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 640 | $533.58 | $341,489.79 |
DisclosureSEC source: 0001106578-26-000103 · primarydocument.xml · nonDerivative · entry 9 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 327,383 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F9 · price: This transaction was executed in multiple trades at prices ranging from $533.08 to $533.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 21, 2026 Filed Jul 22, 2026 20:30 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 360 | $532.47 | $191,688.41 |
DisclosureSEC source: 0001106578-26-000103 · primarydocument.xml · nonDerivative · entry 8 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 328,023 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F8 · price: This transaction was executed in multiple trades at prices ranging from $532.03 to $533.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 21, 2026 Filed Jul 22, 2026 20:30 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 2,605 | $531.52 | $1,384,597.62 |
DisclosureSEC source: 0001106578-26-000103 · primarydocument.xml · nonDerivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 328,383 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F7 · price: This transaction was executed in multiple trades at prices ranging from $531.015 to $531.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 21, 2026 Filed Jul 22, 2026 20:30 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 1,926 | $530.50 | $1,021,743.00 |
DisclosureSEC source: 0001106578-26-000103 · primarydocument.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 330,988 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F6 · price: This transaction was executed in multiple trades at prices ranging from $530.01 to $531.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 21, 2026 Filed Jul 22, 2026 20:30 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 509 | $529.55 | $269,541.31 |
DisclosureSEC source: 0001106578-26-000103 · primarydocument.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 332,914 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F5 · price: This transaction was executed in multiple trades at prices ranging from $528.99 to $529.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 21, 2026 Filed Jul 22, 2026 20:30 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 240 | $527.46 | $126,590.40 |
DisclosureSEC source: 0001106578-26-000103 · primarydocument.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 333,423 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 21, 2026 Filed Jul 22, 2026 20:30 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 160 | $526.24 | $84,198.00 |
DisclosureSEC source: 0001106578-26-000103 · primarydocument.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 333,663 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F4 · price: This transaction was executed in multiple trades at prices ranging from $525.875 to $526.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 21, 2026 Filed Jul 22, 2026 20:30 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 120 | $524.37 | $62,923.97 |
DisclosureSEC source: 0001106578-26-000103 · primarydocument.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 333,823 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F3 · price: This transaction was executed in multiple trades at prices ranging from $523.81 to $524.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 21, 2026 Filed Jul 22, 2026 20:30 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
Exercise / conversionCommon Stock | 9,500 | $135.42 | $1,286,490.00 |
DisclosureSEC source: 0001106578-26-000103 · primarydocument.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 333,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 20:35 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
Exercise / conversionStock Option · Derivative | 9,500 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001106578-26-000102 · primarydocument.xml · derivative · entry 15 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 312,910 Underlying: Common Stock · 9,500 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F13 · ownership.nature: Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 20:35 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 80 | $536.41 | $42,912.80 |
DisclosureSEC source: 0001106578-26-000102 · primarydocument.xml · nonDerivative · entry 9 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 324,443 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 20:35 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 520 | $535.20 | $278,306.29 |
DisclosureSEC source: 0001106578-26-000102 · primarydocument.xml · nonDerivative · entry 8 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 324,523 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F9 · price: This transaction was executed in multiple trades at prices ranging from $534.71 to $535.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 20:35 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 889 | $534.13 | $474,838.37 |
DisclosureSEC source: 0001106578-26-000102 · primarydocument.xml · nonDerivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 325,043 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F8 · price: This transaction was executed in multiple trades at prices ranging from $533.665 to $534.63. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 20:35 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 1,686 | $533.03 | $898,683.18 |
DisclosureSEC source: 0001106578-26-000102 · primarydocument.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 325,932 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F7 · price: This transaction was executed in multiple trades at prices ranging from $532.63 to $533.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 20:35 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 1,874 | $532.07 | $997,104.61 |
DisclosureSEC source: 0001106578-26-000102 · primarydocument.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 327,618 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F6 · price: This transaction was executed in multiple trades at prices ranging from $531.63 to $532.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 20:35 UTC |
ROTHBLATT MARTINE ADirector · Chairperson & CEO
|
SaleCommon Stock | 1,660 | $531.08 | $881,587.99 |
DisclosureSEC source: 0001106578-26-000102 · primarydocument.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 329,492 F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F5 · price: This transaction was executed in multiple trades at prices ranging from $530.60 to $531.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.